Biotech Values

[rfj1862]

NABI

In the course of my day job, I spend substantial time speaking with key opinion leaders in various therapeutic areas. I recently had an opportunity to speak with prominant physicians in the anti-infective field. Never one to waste an opportunity, I asked about StaphVax. "Revolutionary" was one choice quote.

I believe that StaphVax will become a standard vaccine for elderly patients, particularly those at high risk for surgical intervention. Provided the results of the second phase III are as good or better than those of the first phase III, which they should be, StaphVax should be very successful.

I won't get into NicVax--I'm very excited about the potential there, as well.

John